Savior Lifetec announced on March 5 that its flagship antibiotic, Ertapenem, has officially entered the Chinese market—the world’s second-largest. Following its success in the U.S. (where it held the #1 market share in 2025), Savior Lifetec is now challenging for the top global position.

• Market Trends: The rise of antibiotic resistance and the shift toward Outpatient Parenteral Antimicrobial Therapy (OPAT) are accelerating the replacement of brand-name drugs with high-quality generics. Savior Lifetec’s large-batch tray freeze-drying process provides a significant scale advantage.
• Capacity Expansion: To resolve current supply shortages, the company is accelerating the validation of its third production line, aiming for a Q2 2026 launch.
• Financial Resilience: 2025 revenue reached NT$1.202 billion, with gross margins climbing from 28% to 35%. With new capacity and entries into France, Italy, and Argentina, analysts expect 2026 revenue to grow by 10% to 20%.

Resource: 松瑞藥競逐厄他培南全球龍頭廠地位 今年營收拚一至兩成成長